Skip to main content

Table 3 Depression, anxiety, pain and quality of life scores throughout the study period

From: Trazodone for the treatment of fibromyalgia: an open-label, 12-week study

  baseline week 6 week 12 P (anova)
BDI-whole sample (mean ± s.d.) 28.0 ± 10.7 24.9 ± 12.3* 22.5 ± 10.7*** < 0.0001
ES   0.29 0.51  
BDI > 18 (N = 41) (mean ± s.d.) 31 ± 9.2 26.9 ± 12.0* 23.3 ± 10.1*** < 0.0001
ES   0.45 0.84  
HADS-depression (mean ± s.d.) 12.4 ± 4.9 11.6 ± 4.8 11.0 ± 5.0** = 0.0142
ES   0.16 0.29  
HADS depression > 7 (N = 43) (mean ± s.d.) 13.6 ± 3.8 12.5 ± 4.2 11.6 ± 4.5** = 0.0054
ES   0.29 0.53  
HADS anxiety (mean ± s.d.) 13.8 ± 4.2 13.1 ± 4.7 12.3 ± 4.9** = 0.0041
ES   0.17 0.36  
HADS anxiety >7 (N = 47) (mean ± s.d.) 14.5 ± 3.4 13.6 ± 4.3 12.7 ± 4.4** = 0.0061
ES   0.26 0.53  
BPI: mean pain severity (mean ± s.d.) 7.47 ± 1.6 7.00 ± 1.8* 6.95 ± 1.8* = 0.0154
ES   0.29 0.33  
BPI: pain interference with daily activities (mean ± s.d.) 8.42 ± 1.7 7.11 ± 2.2*** 6.82 ± 2.6*** < 0.0001
ES   0.66 0.84  
SF-36: PCS (mean ± s.d.) 27.3 ± 4.1   28.2 ± 5.2 N.S.
ES    -0.22  
SF-36: MCS (mean ± s.d.) 28.0 ± 11.5   30.7 ± 12.5* = 0.0383
ES    -0.23  
  1. *: p < 0.05, **:p < 0.01, and ***: p < 0.001 in relation to baseline (Dunnett's post-test)
  2. ES: effect size; bold: moderate and large effect sizes